Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020. [published online ahead of print].
   Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19. Int J Surg. 2020;76:71–76.
   PubMed Web of Science ®Google Scholar
• Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020;92(6):612–617.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020. [published online ahead of print].
   Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China: Guidelines for novel coronavirus infection prevention and treatment (Trial 7th edition). Available from: https://wwwchinalawtranslatecom/en/coronavirus-treatment-plan-7/.
   Google Scholar
• Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518–1519.
   PubMed Web of Science ®Google Scholar
• Wang YD, Zhang SP, Wei QZ, et al. COVID-19 complicated with DIC: 2 cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E001.
   PubMedGoogle Scholar
• Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838.
   PubMedGoogle Scholar
• Hatem AA, Mahmoud MM, Sohail AS, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Renal Failure. 2020;42(1):393–397.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu M, Yao J, et al. Caution on kidney dysfunctions of 2019-nCoV patients. MedRxiv. 2020. DOI:https://doi.org/10.1101/2020.02.08.20021212
   Google Scholar
• Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017;69(6):1135–1143.
   PubMed Web of Science ®Google Scholar
• Wang C, Xie J, Zhao L, et al. Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19. Preprint from Research Square, 2020. DOI:https://doi.org/10.21203/rs.3.rs-19346/v1
   Google Scholar
• Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175–180.
   PubMed Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980–991.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10.
   PubMed Web of Science ®Google Scholar
• Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–194.
   PubMed Web of Science ®Google Scholar
• Henter JI, Chow CB, Leung CW, et al. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet. 2006;367(9513):870–873.
   PubMed Web of Science ®Google Scholar
• Chi Y, Zhu Y, Wen T, et al. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis. 2013;208(12):1962–1967.
   PubMed Web of Science ®Google Scholar
• Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol. 2017;39(5):541–550.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Poulakou G, Perez M, Rello J. Severe acute respiratory infections in the postpandemic era of H1N1. Curr Opin Crit Care. 2012;18(5):441–450.
   PubMed Web of Science ®Google Scholar
• Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277–2285.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Richard JC, Mercat A, Group R-SAHNvR, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(9):1200–1206.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Cha RH, Joh JS, Jeong I, et al. Critical Care Team of National Medical Center. Renal Complications and their prognosis in Korean patients with middle east respiratory syndrome-coronavirus from the central MERS-CoV designated hospital. J Korean Med Sci. 2015;30(12):1807–1814.
   PubMed Web of Science ®Google Scholar
• Silvester W. Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis. 1997;30(5 Suppl 4):S38–S43.
   PubMed Web of Science ®Google Scholar
• Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315(20):2190–2199.
   PubMed Web of Science ®Google Scholar
• Barbar SD, , Clere-Jehl R, Bourredjem A, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. 2018;379(15):1431–1442.
   PubMed Web of Science ®Google Scholar
• Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356(9223):26–30.
   PubMed Web of Science ®Google Scholar
• Network V, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;3(359(1):7–20.
   Google Scholar
• Investigators R, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361(17):1627–1638.
   PubMed Web of Science ®Google Scholar
• Joannes-Boyau O, Honore PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39(9):1535–1546.
   PubMed Web of Science ®Google Scholar
• Li Y, Li H, Zhang D. Timing of continuous renal replacement therapy in patients with septic AKI: a systematic review and meta-analysis. Medicine. 2019;98(33):e16800.
   PubMed Web of Science ®Google Scholar
• Morgera S, Haase M, Rocktaschel J, et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. 2003;18(12):2570–2576.
   PubMed Web of Science ®Google Scholar
• Morgera S, Rocktaschel J, Haase M, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med. 2003;29(11):1989–1995.
   PubMed Web of Science ®Google Scholar
• Atan R, Peck L, Prowle J, et al. A double-blind randomized controlled trial of high cutoff versus standard hemofiltration in critically ill patients with acute kidney injury. Crit Care Med. 2018;46(10):e988–e94.
   PubMed Web of Science ®Google Scholar
• Yumoto M, Nishida O, Moriyama K, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial. 2011;15(4):385–393.
   PubMed Web of Science ®Google Scholar
• Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6(1):12.
   PubMedGoogle Scholar
• Shum HP, Chan KC, Kwan MC, et al. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med J. 2013;19(6):491–497.
   PubMed Web of Science ®Google Scholar
• Schwindenhammer V, Girardot T, Chaulier K, et al. oXiris(R) use in septic shock: experience of two french centres. Blood Purif. 2019;47(3):1–7.
   PubMedGoogle Scholar
• Turani F, Barchetta R, Falco M, et al. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif. 2019;47(3):1–5.
   Google Scholar
• Zhang L, Yan Tang GK, Liu S, et al. Hemofilter with adsorptive capacities: case report series. Blood Purif. 2019;47(3):1–6.
   Google Scholar
• Livigni S, Bertolini G, Rossi C, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014;4(1):e003536.
   PubMed Web of Science ®Google Scholar
• Kogelmann K, Jarczak D, Scheller M, et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21(1):74.
   PubMedGoogle Scholar
• Brouwer WP, Duran S, Kuijper M, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23(1):317.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020. [published online ahead of print].
   Web of Science ®Google Scholar
• Sieberth HG, Kierdorf HP. Is cytokine removal by continuous hemofiltration feasible?. Kidney Int Suppl. 1999;56(72):S79–S83.
   Google Scholar
• Quenot JP, Binquet C, Vinsonneau C, et al. Very high volume hemofiltration with the Cascade system in septic shock patients. Intens Care Med. 2015;41(12):2111–2120.
   PubMed Web of Science ®Google Scholar